skip to main content
Cargill Logo
Cargill
  • Our Stories
  • About Cargill

    About Cargill

    • Thrive Stories
    • Company Overview
    • Executive Team
    • 2022 Annual Report
    • Our History
    • Community Engagement
    • Research & Development
    • Diversity, Equity and Inclusion
    • Workplace Safety
    • Ethics & Compliance
    • Supplier Central
    • Contact Us
  • Sustainability

    Sustainability

    • Supply Chains
    • Sustainability Priorities
    • 2022 ESG Report
    • Reporting Hub
    • Newsletter signup
    • Innovation that Sustains
  • Products & Services

    Products & Services

    • Agriculture
    • Animal Nutrition
    • Beauty
    • Bioindustrial
    • Foodservice
    • Food & Beverage
    • Industrial
    • Pharmaceutical
    • Meat & Poultry
    • Risk Management
    • Supplements
    • Transportation
  • News

    News

    • All Press Releases
    • Company Statements
    • In The News
  • Careers
  • Worldwide
  • Contact
Home/Products & Services/Supplements/EpiCor® Postbiotic/Winter Trials Abstracts
  • Supplements
    • EpiCor® Postbiotic
      • Contact Us
      • Download EpiCor® Resources
      • FAQs
      • Sales & Distribution
 
ColorBlock Hero Sizer

Winter Trials Abstracts

Effects of a modified yeast supplement on cold/flu symptoms

1. Moyad, M. A.,  et al. Effects of a modified yeast supplement on cold/flu symptoms. Urol Nurs 2008, 28 (1), 50-5. [Online reference: http://www.ncbi.nlm.nih.gov/pubmed/18335698]

A yeast-based product (EpiCor, a dried Saccharomyces cerevisiae fermentate) was compared to placebo to determine effects on the incidence and duration of cold and flu-like symptoms in healthy subjects recently vaccinated for seasonal influenza. In a 12-week, randomized, double-blind, placebo-controlled clinical trial, 116 participants received daily supplementation with 500 mg of EpiCor or placebo for 12 weeks. Data collected included periodic in-clinic examinations and serologic evaluations at baseline, 6- and 12-weeks. Subjects also utilized a standardized self-report symptom diary during the study. Participants receiving the yeast-based product had significantly fewer symptoms and significantly shorter duration of symptoms when compared with subjects taking a placebo.

2. Moyad, M. A., et all.  Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. J Altern Complement Med 2010, 16 (2), 213-8. [Online reference: https://pubmed.ncbi.nlm.nih.gov/20180695/] 

Background: The common cold has a profound impact on employee attendance and productivity. Seasonal influenza is responsible for approximately 200,000 hospitalizations and 36,000 deaths per year in the United States alone. Over-the-counter medication efficacy has been questioned, and seasonal vaccination compliance issues abound. Our previously reported randomized trial of an oral fermentation product found an adjuvant benefit for vaccinated individuals in terms of a significantly reduced incidence and duration of cold and flu-like symptoms.

 

EpiCor Postbiotic Research Study - EpiCor Impacts Cold and Flu Symptoms on Healthy Adults

Download Report

Methods: A concurrent 12-week, randomized, double-blind, placebo-controlled clinical trial of 116 subjects with no recent history of seasonal influenza vaccination was conducted. Participants received once-daily supplementation with 500 mg of a dried modified Saccharomyces cerevisiae oral fermentate (EpiCor) or placebo. Clinical outcome measurements included periodic interval-based in-clinic examinations and serologic analysis at baseline, 6 weeks, and 12 weeks. Participants utilized a standardized self-report symptom diary.

Results: Subjects receiving the intervention experienced a statistically significant reduction in the incidence (p = 0.01), a nonsignificant reduction in duration (p = 0.10), and no impact on the severity (p = 0.90) of colds or flu-like symptoms, but a more favorable safety profile compared with subjects receiving placebo.

   

 

 

 

Some Cargill products are only approved for use in certain geographies, end uses, and/or at certain usage levels. It is the customer's responsibility to determine, for a particular geography, that (i) the Cargill product, its use and usage levels, (ii) the customer's product and its use, and (iii) any claims made about the customer's product, all comply with applicable laws and regulations.

Twitter Facebook Linkedin YouTube Instagram
Contact Worldwide
Privacy Notices Fraud Notice
Website Terms of Use Purchase Order Terms
© 2023 Cargill, Incorporated. All Rights Reserved.